biomarkers
In Search of Psychosis Biomarkers in High-risk Populations: Is the Mismatch Negativity the One We've Been Waiting for?
In this issue of Biological Psychiatry, Atkinson et al. () describe alterations in early preattentive brain electrical activity in individuals meeting criteria for ultrahigh risk (UHR) for the development of psychosis. Identifying biological markers in high-risk populations is a critical step toward informing about the pathophysiology of the disorder, predicting onset of psychosis, and potentially devising early interventions to change the course of the illness. The auditory mismatch negativity (MMN) described by Atkinson et al.
Biomarkers for Insulin Resistance and Inflammation and the Risk for All-Cause Dementia and Alzheimer Disease: Results From the Framingham Heart Study [Original Contribution]
Objective To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia.
Design Prospective cohort study.
Evidence for Ordering of Alzheimer Disease Biomarkers [Original Contribution]
Objective To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner.
Design Validation sample.
Setting Multisite, referral centers.
Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder [Original Article]
Context The administration of nicotine transiently improves many neurobiological and cognitive functions in schizophrenia and schizoaffective disorder. It is not yet clear which nicotinic acetylcholine receptor (nAChR) subtype or subtypes are responsible for these seemingly pervasive nicotinic effects in schizophrenia and schizoaffective disorder.
Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains
Abstract
Rationale Identification of biomarkers that establish diagnosis or treatment response is critical to the advancement of research and
management of patients with depression.
Objective Our goal was to identify biomarkers that can potentially assess fluoxetine response and risk to poor treatment outcome.
Methods We measured behavior, gene expression, and the levels of 36 neurobiochemical analytes across a panel of genetically diverse
mouse inbred lines after chronic tr
Alzheimer disease biomarkers are associated with body mass index
Objective:
Both low and high body mass index (BMI) has been associated with cognitive impairment and dementia risk, including Alzheimer disease (AD). We examined the relationship of BMI with potential underlying biological substrates for cognitive impairment.
Biomarkers for Mental Disorders: A Field Whose Time Has Come
Biomarkers for mental disorders is a field whose time has come. Optimists will say within a few years, pessimists might say a decade or beyond.
Predicting MCI outcome with clinically available MRI and CSF biomarkers
Objective:
To determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer disease (AD) in patients with mild cognitive impairment (MCI).
Translating biomarkers to clinical practice
Translating biomarkers to clinical practice
Molecular Psychiatry 16,
1076 (November 2011). doi:10.1038/mp.2011.63
Author: R H Perlis